HomeCompareTTNP vs GBDC

TTNP vs GBDC: Dividend Comparison 2026

TTNP yields 85.47% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $18.66M in total portfolio value· pulled ahead in Year 8
10 years
TTNP
TTNP
● Live price
85.47%
Share price
$2.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.11M
Annual income
$639,398.81
Full TTNP calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — TTNP vs GBDC

📍 GBDC pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTNPGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTNP + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTNP pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTNP
Annual income on $10K today (after 15% tax)
$7,264.96/yr
After 10yr DRIP, annual income (after tax)
$543,488.99/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,387,384.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTNP + GBDC for your $10,000?

TTNP: 50%GBDC: 50%
100% GBDC50/50100% TTNP
Portfolio after 10yr
$11.44M
Annual income
$8,514,331.10/yr
Blended yield
74.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TTNP
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-240.6
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTNP buys
0
GBDC buys
0
No recent congressional trades found for TTNP or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTNPGBDC
Forward yield85.47%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$2.11M$20.78M
Annual income after 10y$639,398.81$16,389,263.41
Total dividends collected$1.85M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: TTNP vs GBDC ($10,000, DRIP)

YearTTNP PortfolioTTNP Income/yrGBDC PortfolioGBDC Income/yrGap
1$19,247$8,547.01$12,490$1,790.28+$6.8KTTNP
2$35,969$15,374.24$16,522$3,157.73+$19.4KTTNP
3$65,338$26,851.55$23,578$5,898.68+$41.8KTTNP
4$115,497$45,585.62$37,115$11,886.75+$78.4KTTNP
5$198,892$75,309.60$66,136$26,423.57+$132.8KTTNP
6$334,016$121,202.50$137,257$66,491.44+$196.8KTTNP
7$547,628$190,230.15$341,734$194,868.54+$205.9KTTNP
8← crossover$877,445$291,482.95$1,050,788$685,133.02$173.3KGBDC
9$1,375,345$436,479.30$4,099,314$2,974,971.01$2.72MGBDC
10$2,111,018$639,398.81$20,775,530$16,389,263.41$18.66MGBDC

TTNP vs GBDC: Complete Analysis 2026

TTNPStock

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Full TTNP Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TTNP vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTNP vs SCHDTTNP vs JEPITTNP vs OTTNP vs KOTTNP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.